K. Klesczewski

682 total citations
10 papers, 546 citations indexed

About

K. Klesczewski is a scholar working on Epidemiology, Hepatology and Infectious Diseases. According to data from OpenAlex, K. Klesczewski has authored 10 papers receiving a total of 546 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Epidemiology, 6 papers in Hepatology and 4 papers in Infectious Diseases. Recurrent topics in K. Klesczewski's work include Hepatitis B Virus Studies (6 papers), Hepatitis C virus research (5 papers) and HIV/AIDS drug development and treatment (4 papers). K. Klesczewski is often cited by papers focused on Hepatitis B Virus Studies (6 papers), Hepatitis C virus research (5 papers) and HIV/AIDS drug development and treatment (4 papers). K. Klesczewski collaborates with scholars based in United States, Taiwan and France. K. Klesczewski's co-authors include Richard J. Colonno, Ronald E. Rose, Daniel J. Tenney, Carl J. Baldick, Steven M. LeVine, Cheng Fang Yu, Kevin A. Pokornowski, Charles E. Mazzucco, Jie Fang and Sharon Zhang and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Gastroenterology.

In The Last Decade

K. Klesczewski

10 papers receiving 524 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
K. Klesczewski United States 7 514 505 82 24 12 10 546
A.R. Türkyilmaz Türkiye 9 368 0.7× 359 0.7× 67 0.8× 9 0.4× 3 0.3× 15 394
Josep M. Guardiola Spain 11 273 0.5× 324 0.6× 184 2.2× 10 0.4× 11 0.9× 25 423
Cecilia Marrocco Italy 11 454 0.9× 466 0.9× 65 0.8× 4 0.2× 5 0.4× 15 500
Shigeru Yotsumoto Japan 8 382 0.7× 372 0.7× 60 0.7× 13 0.5× 2 0.2× 11 415
Monique Chaneac Italy 6 420 0.8× 469 0.9× 43 0.5× 6 0.3× 23 1.9× 7 496
Eirum Chaudhri Japan 3 437 0.9× 509 1.0× 113 1.4× 6 0.3× 15 1.3× 3 531
J. McHutchison United States 11 290 0.6× 315 0.6× 81 1.0× 7 0.3× 14 1.2× 42 341
Beatriz Calle Serrano Germany 7 568 1.1× 561 1.1× 51 0.6× 4 0.2× 6 0.5× 9 605
Karl‐Georg Simon Germany 11 515 1.0× 519 1.0× 85 1.0× 4 0.2× 7 0.6× 33 550
Lorena De Moliner Italy 10 366 0.7× 374 0.7× 17 0.2× 13 0.5× 10 0.8× 13 429

Countries citing papers authored by K. Klesczewski

Since Specialization
Citations

This map shows the geographic impact of K. Klesczewski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by K. Klesczewski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites K. Klesczewski more than expected).

Fields of papers citing papers by K. Klesczewski

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by K. Klesczewski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by K. Klesczewski. The network helps show where K. Klesczewski may publish in the future.

Co-authorship network of co-authors of K. Klesczewski

This figure shows the co-authorship network connecting the top 25 collaborators of K. Klesczewski. A scholar is included among the top collaborators of K. Klesczewski based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with K. Klesczewski. K. Klesczewski is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

10 of 10 papers shown
1.
Cappellini, Maria Domenica, John B. Porter, Raffaella Origa, et al.. (2013). A Phase 2a, Open-Label, Dose-Finding Study To Determine The Safety and Tolerability Of Sotatercept (ACE-011) In Adults With Beta (β)-Thalassemia: Interim Results. Blood. 122(21). 3448–3448. 14 indexed citations
2.
Matous, Jeffrey, David S. Siegel, Hien K. Duong, et al.. (2013). MM-008 trial: Pharmacokinetics (PK) and tolerability of pomalidomide plus low-dose dexamethasone (POM plus LoDEX) in relapsed/refractory multiple myeloma (RRMM) patients with renal impairment (RI).. Journal of Clinical Oncology. 31(15_suppl). 8585–8585. 9 indexed citations
3.
4.
Şimşek, Halis, et al.. (2007). [518] EFFICACY OF ENTECAVIR AND LAMIVUDINE IN CHRONIC HEPATITIS B PATIENTS WITH ADVANCED FIBROSIS/CIRRHOSIS. Journal of Hepatology. 46. S197–S197. 3 indexed citations
5.
Colonno, Richard J., Ronald E. Rose, Carl J. Baldick, et al.. (2006). Entecavir resistance is rare in nucleoside naïve patients with hepatitis B. Hepatology. 44(6). 1656–1665. 276 indexed citations
6.
7.
Colonno, Richard J., R.E. Rose, Carl J. Baldick, et al.. (2006). 490 High barrier to resistance results in no emergence of entecavir resistance in nucleoside-naïve subjects during the first two years of therapy. Journal of Hepatology. 44. S182–S182. 15 indexed citations
8.
Chang, Ting‐Tsung, Robert G. Gish, Stephanos J. Hadziyannis, et al.. (2005). A Dose-Ranging Study of the Efficacy and Tolerability of Entecavir in Lamivudine-Refractory Chronic Hepatitis B Patients. Gastroenterology. 129(4). 1198–1209. 199 indexed citations
9.
Gish, Robert G., Stephanos J. Hadziyannis, J Cianciara, et al.. (2003). Sustained viral load and ALT reduction following 48 weeks of entecavir treatment in HBEAG-negative and -positive patients with chronic hepatitis B who have failed prior lamivudine therapy. Journal of Hepatology. 38. 32–33. 6 indexed citations
10.
Chang, Ting‐Tsung, S. Hadziyannis, J Cianciara, et al.. (2002). Sustained viral load and ALT reduction following 48 weeks of entecavir treatment in subjects with chronic hepatitis B who have failed lamivudine.. Hepatology. 36(4). 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by A.R. Türkyilmaz Breakdown of academic impact, for papers by Josep M. Guardiola Breakdown of academic impact, for papers by Cecilia Marrocco Breakdown of academic impact, for papers by Shigeru Yotsumoto Breakdown of academic impact, for papers by Monique Chaneac Breakdown of academic impact, for papers by Eirum Chaudhri Breakdown of academic impact, for papers by J. McHutchison Breakdown of academic impact, for papers by Beatriz Calle Serrano Breakdown of academic impact, for papers by Karl‐Georg Simon Breakdown of academic impact, for papers by Lorena De Moliner
Rankless by CCL
2026